Arvinas (NASDAQ:ARVN) CAO David Loomis Sells 1,016 Shares

Arvinas, Inc. (NASDAQ:ARVN) CAO David Loomis sold 1,016 shares of the firm’s stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $11.89, for a total transaction of $12,080.24. Following the completion of the transaction, the chief accounting officer owned 30,800 shares in the company, valued at $366,212. The trade was a 3.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Arvinas Stock Up 3.3%

Shares of ARVN stock traded up $0.38 during mid-day trading on Wednesday, reaching $11.82. The company’s stock had a trading volume of 559,743 shares, compared to its average volume of 759,739. The firm has a market capitalization of $759.13 million, a PE ratio of -14.59 and a beta of 1.88. The company’s 50 day simple moving average is $12.40 and its 200-day simple moving average is $10.32. Arvinas, Inc. has a 12-month low of $5.90 and a 12-month high of $19.40.

Institutional Trading of Arvinas

Several institutional investors have recently added to or reduced their stakes in ARVN. TCG Crossover Management LLC bought a new position in Arvinas during the 3rd quarter worth approximately $13,780,000. Acadian Asset Management LLC raised its position in shares of Arvinas by 791.1% during the 2nd quarter. Acadian Asset Management LLC now owns 1,427,832 shares of the company’s stock valued at $10,498,000 after acquiring an additional 1,267,593 shares in the last quarter. Balyasny Asset Management L.P. lifted its stake in Arvinas by 469.1% during the third quarter. Balyasny Asset Management L.P. now owns 1,207,267 shares of the company’s stock worth $10,286,000 after purchasing an additional 995,125 shares during the last quarter. Qube Research & Technologies Ltd lifted its stake in Arvinas by 154.8% during the third quarter. Qube Research & Technologies Ltd now owns 1,486,864 shares of the company’s stock worth $12,668,000 after purchasing an additional 903,337 shares during the last quarter. Finally, Millennium Management LLC boosted its holdings in Arvinas by 208.4% in the first quarter. Millennium Management LLC now owns 1,310,326 shares of the company’s stock worth $9,198,000 after purchasing an additional 885,483 shares during the period. 95.19% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on ARVN. Wall Street Zen lowered Arvinas from a “hold” rating to a “sell” rating in a research note on Saturday. BTIG Research increased their price objective on shares of Arvinas from $10.00 to $14.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Arvinas in a research report on Monday, December 22nd. Wedbush reaffirmed a “neutral” rating and set a $9.00 price target on shares of Arvinas in a report on Thursday, November 6th. Finally, Citigroup upgraded shares of Arvinas from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $10.00 to $15.00 in a report on Tuesday, January 6th. Ten investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Arvinas currently has a consensus rating of “Hold” and a consensus price target of $13.12.

Arvinas Company Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.